<p>New York, New York--(Newsfile Corp. - July 27, 2026) - <a href="https://api.newsfilecorp.com/redi...

<p>New York, New York--(Newsfile Corp. - July 27, 2026) - <a href="https://api.newsfilecorp.com/redirect/bgLjvcaVpe">Kaplan Fox &#38; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) on behalf of investors that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026 (the "Class Period").</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/3KAWyCEKZ4">CLICK HERE TO JOIN THE CASE</a></p><p><b>If you are an investor in Erasca and have suffered losses, you may </b><a href="https://api.newsfilecorp.com/redirect/N3pzMiNA2n"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <u><b>no later than August 10, 2026</b></u> to serve as a lead plaintiff for the purported class.  If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p><p>According to the complaint, on April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed") alleging that Erasca's ERAS-0015 infringes a RevMed patent and is connected to alleged trade secret misappropriation. Further, according to the complaint, RevMed also alleged that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanded Erasca cease making "deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236." The Company has stated that it believes the assertions are without merit and intends to contest the allegations.</p><p>On this news, the price of Erasca stock fell $2.34 per share, nearly 11%, to close at $19.15 per share on April 27, 2026.</p><p>The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this Notice, your rights, or your interests, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/XE45etPr2M">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/DOm8etnvKn">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/rp4zDfqz1a">https://www.kaplanfox.com/case/erasca-inc-class-action-alert-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/306702_f0e44589b4dd98ba_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/VvVkeUYRrv">https://www.newsfilecorp.com/release/306702</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/306702/197" alt="" /></p>

ERAS

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

Erasca faces securities-class action over ERAS-0015 data, risk to valuation

LOS ANGELES, July 28, 2026 /PRNewswire/ -- Schall Brown &amp; Schwartz LLP,a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. (&#34;Erasca&#34; or &#34;the

Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p&gt;New York, New York--(Newsfile Corp. - July 27, 2026) - &lt;a href=&quot;https://api.newsfilecorp.com/redi...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>A securities class action accuses Erasca of misrepresenting ERAS-0015 data and improper preclinical comparisons to Revolution Medicines. The news triggered an 11% drop to $19.15 on April 27, 2026, highlighting immediate headline risk. The August 10, 2026 deadline for lead plaintiffs keeps near-term focus on potential litigation outcomes and cash-flow implications.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox files Erasca class action over ERAS-0015 data concerns.</li><li>Alleges improper preclinical data comparisons to Revolution Medicines; claims misstatements.</li><li>Erasca stock fell 11% to $19.15 on April 27, 2026.</li><li>Lead plaintiff deadline: August 10, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Erasca, Inc. (ERAS)</strong>: Subject of a securities class action alleging misstatements related to ERAS-0015.</li><li><strong>Revolution Medicines, Inc. (RVMD)</strong>: Alleged patent/trade secret issues linked to ERAS-0015 through disclosed letter.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. Fits because a securities-class-action press release can shift investor sentiment and stock volatility; legal risk may affect ERAS-0015&#039;s perceived value and future approvals or partnerships.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Legal action introduces headline risk and potential valuation impact.</li><li>RevMed patent dispute adds liability to ERAS-0015 disclosures.</li><li>Stock declined 11% on the news, signaling market sensitivity.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Class Period: January 14, 2025 – April 26, 2026.</li><li>Stock fell $2.34, 11%, to $19.15 on April 27, 2026.</li><li>Lead Plaintiff deadline: August 10, 2026.</li><li>Plaintiff law firm: Kaplan Fox &amp; Kilsheimer LLP.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>ERAS may remain volatile near the August 2026 lead-plaintiff deadline with downside risk.</p>
  </section>
</section>


<article>
  <section>
    <h2>ERAS Class Action Filed Against Erasca, Inc. (ERAS) as Investors Urged to Seek Lead Plaintiff Roles by August 10, 2026</h2>
    <p>New York, New York — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. (<strong>ERAS</strong>) on behalf of investors who purchased or acquired Erasca securities between <strong>January 14, 2025</strong> and <strong>April 26, 2026</strong> (the “Class Period”).</p>
    <p>The filing underscores alleged misstatements and omissions related to <em>ERAS-0015</em> and its preclinical data, with the firm inviting eligible investors to join the case. The action targets claims that the Company and related defendants made false or misleading statements during the Class Period.</p>
  </section>

  <section>
    <h3>Case Details: Class Period, Ticker, and Filing</h3>
    <ul>
      <li><strong>Stock symbol:</strong> ERAS</li>
      <li><strong>Company:</strong> Erasca, Inc.</li>
      <li><strong>Class Period:</strong> January 14, 2025 to April 26, 2026</li>
      <li><strong>Filing date:</strong> July 27, 2026 (as disclosed in the press release)</li>
    </ul>
    <p><strong>Deadline reminder:</strong> If you are a member of the proposed Class, you may move the court <u><strong>no later than August 10, 2026</strong></u> to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.</p>
  </section>

  <section>
    <h3>Allegations, Disclosures, and Company Response</h3>
    <p>According to the complaint, on <strong>April 27, 2026</strong>, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. (<em>RevMed</em>) alleging that Erasca's <em>ERAS-0015</em> infringes a RevMed patent and is connected to alleged trade secret misappropriation. Further, the complaint states that RevMed alleged Erasca had <em>"improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures"</em> and demanded Erasca cease making <em>"deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236."</em> The Company has stated that it believes the assertions are without merit and intends to contest the allegations.</p>
    <p>On this news, the price of Erasca stock fell <strong>$2.34 per share</strong>, nearly <strong>11%</strong>, to close at <strong>$19.15 per share</strong> on <strong>April 27, 2026</strong>.</p>
    <p>The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that <em>(1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.</em></p>
  </section>

  <section>
    <h3>Why Contact Kaplan Fox?</h3>
    <p>Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than <strong>$10 billion</strong> for clients and the classes it has represented.</p>
    <p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. The firm has secured some of the largest recoveries in the history of securities litigation, including a <strong>$2.425 billion</strong> recovery on behalf of Bank of America shareholders in <em>In re Bank of America</em>—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act; <strong>$800 million</strong> recovered for the Arkansas Teacher Retirement System and other pension funds in <em>ATRS v. Allianz Global Investors</em>, and a <strong>$475 million</strong> settlement in <em>In re Merrill Lynch</em>.</p>
    <p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p>
    <p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p>
  </section>

  <section>
    <h3>How to Participate or Learn More</h3>
    <p>If you have any questions about this notice, your rights, or your interests, please contact:</p>
    <div id="contactInfo">
      <p><strong>CONTACT:</strong><br />
      Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/XE45etPr2M">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />
      800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p>
      <p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/DOm8etnvKn">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p>
    </div>
    <p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p>
  </section>

  <section>
    <h3>Source and Corporate Information</h3>
    <p><a href="https://www.kaplanfox.com/case/erasca-inc-class-action-alert-learn-more-now/">https://www.kaplanfox.com/case/erasca-inc-class-action-alert-learn-more-now/</a></p>
    <p><img src="https://images.newsfilecorp.com/files/12532/306702_f0e44589b4dd98ba_logo.jpg" alt="Corporate Logo" /></p>
    <p>To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/release/306702">https://www.newsfilecorp.com/release/306702</a></p>
  </section>
</article>

A securities class action accuses Erasca of misrepresenting ERAS-0015 data and improper preclinical comparisons to Revolution Medicines. The news triggered an 11% drop to $19.15 on April 27, 2026, highlighting immediate headline risk. The August 10, 2026 deadline for lead plaintiffs keeps near-term focus on potential litigation outcomes and cash-flow implications.

News insight

Kaplan Fox Urges Investors of Erasca, Inc. (ERAS) with Significant Losses to Seek a Leadership Role Before August 10, 2026

AI summary

Sentiment rationale

Key facts

Legal